Neutralizing Antibody Targets ETX Toxin in MS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) do not effectively address the underlying cause of nascent lesion formation, which is believed to be triggered by epsilon toxin (ETX) produced by Clostridium perfringens types B or D, as existing therapies fail to target the toxin's mechanism of action on the blood-brain barrier and myelin cells.
Innovation Solution
Development of a neutralizing antibody specifically targeting epsilon toxin (ETX) that binds to its receptor, the tetraspan integral membrane protein MAL, to prevent or treat MS by inhibiting ETX's toxic effects on oligodendrocytes and the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MS therapies are used, then general immune modulation is achieved, but they fail to target the specific mechanism of ETX action on the blood-brain barrier and myelin cells
Solution Approach 1:
The patent uses neutralizing antibodies as intermediary agents that specifically bind to epsilon toxin, preventing it from interacting with its receptor on oligodendrocytes and blood-brain barrier cells. This intermediary approach allows selective neutralization of the toxic mechanism without broadly suppressing the immune system, thereby achieving both reliability in treating MS pathology and specificity to the ETX mechanism.
Solution Approach 2:
The invention changes the therapeutic parameter from general immune modulation to specific toxin neutralization. By introducing antibodies that specifically bind to ETX, the treatment mechanism shifts from non-specific immune suppression to targeted neutralization of the pathogenic toxin, improving both effectiveness and mechanism-specificity.
2Object-affected harmful factors
If neutralizing antibodies against ETX are administered, then specific protection against toxin-mediated damage is achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts and neutralizes the specific harmful component (epsilon toxin) from the complex pathogenic process of MS. By administering antibodies that specifically bind to ETX, the treatment removes the toxic effect of the toxin without needing to address the entire disease mechanism, thereby protecting against harmful effects while maintaining relatively simple targeted therapy.
3Ease of operation
If current MS treatments are used, then symptom management is achieved, but the underlying cause of nascent lesion formation triggered by ETX is not addressed
Solution Approach 1:
The patent applies preliminary action by neutralizing the epsilon toxin before it can cause nascent lesion formation. The antibodies are administered to prevent the toxin from binding to its receptor on oligodendrocytes and blood-brain barrier cells, thereby addressing the underlying cause of lesion formation before damage occurs, rather than merely managing symptoms after lesions have formed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The neutralizing antibody effectively blocks ETX's binding to its receptor, reducing oligodendrocyte death and BBB disruption, thereby preventing or treating MS by targeting the toxin's specific mechanism of action, providing a therapeutic solution for MS pathogenesis.
Implementation Method 1
a neutralising antibody against epsilon toxin (ETX) produced by Clostridium perfringens type B or type D bacterial strain for use in preventing or treating multiple sclerosis (MS)
Data Source
Figure 1
Figure 2~3F
Figure 4A~4B
AI summary
The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin- logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).